These findings suggest that COL6A3 is a candidate biomarker and a potential mediator of embelin activity.<h4>Conclusion</h4>This study underscores the integration of AI, multi-omics, and <i>in vitro</i> studies for the discovery of candidate biomarkers and mechanistic insights into pathway modulation by Embelin in colorectal cancer. The gene discussed is COL6A3; the disease is colorectal cancer.